March 8, 2012
The U.S. Patent and Trademark Office has rejected all claims made by MonoSol Rx in the third MonoSol patent that the New Jersey company alleged BDSI had infringed. In total, MonoSol had made 222 claims covering three of its patents.
Updated March 6, 2012
Bandwidth.com division Inetwork expands management team; BDSI says it prevails in patent fight; SAS makes knowledge management firm list; Precision files patent suit; Noval Clinical division adds new exec; SlickEdit to tout software to gamers.
February 23, 2012
Specialty pharmaceutical company BDSI says the USPTO has rejected all of the claims asserted by rival MonoSol in the latest patent claim. Both companies have technologies that deliver drugs via a small piece of film that dissolves in the mouth.
How BDSI technology works
February 16, 2012
BioDelivery Sciences' patent for its drug delivery technology triggers a milestone payment from its partner Endo Pharmaceuticals.
February 6, 2012
The Raleigh-based specialty pharmaceutical company has filed a shelf registration that would allow BDSI to raise up to $40 million by selling stock if it needs the money.
Updated January 6, 2012
The Raleigh-based company receives an upfront payment of $30 million from Endo Pharmaceuticals for rights to its treatment technology for chronic pain.
Updated January 2, 2012
Some opioid painkillers used by cancer patients are governed by U.S. Food and Drug Administration plans to manage possible health risks. The FDA is changing how it manages these drugs and these changes should help BDSI.
November 29, 2011
The US Patent and Trademark Office has rejected all 191 claims made by New Jersey-based MonoSol Rx as unpatentable. The dispute centers on the technology that forms BDSI's drug delivery platform.
November 16, 2011
The company has $15.1 million in cash. But the Raleigh-based firm is working on two clinical-stage drug programs and it doesn't have enough money to pay for both of them.
Updated November 11, 2011
"We believe we are on course to become one of the first products to compete with Suboxone, a product with sales in excess of a billion dollars annually and currently without competition," CEO Mark Sirgo says.
September 29, 2011
The Raleigh-based company also says potential partners are still interested in the pain reliver.
September 29, 2011
The chronic pain reliver didn't perform better than a placebo in a Phase 3 clinical trial, but the Raleigh company isn'r giving up.
August 24, 2011
The Raleigh-based drug firm gears to sell breakthrough cancer pain reliver after working through production problems.
October 20, 2010
The decision means $2.5 million in milestone payment for the Raleigh firm.
September 7, 2010
Benny Ward takes over as business and strategic development director at the drug delivery technology development firm.
May 10, 2010
The Raleigh-based firm can now sell its “breakthrough” pain killer drug outside of the U.S. It is seeking approval to sell Onsolis in Europe.
Updated April 20, 2010
The announced sale sends BDSI shares down 14 percent from Monday’s closing price of $4.21 per share.